AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

NZD outlook: 2025 more about surviving
Markets

NZD outlook: 2025 more about surviving

The kiwi shed more than 11% in 2024, and we already see more downsides. 

Rate decision odds are tight, NZD set for a wild ride
Markets Best of BusinessDesk

Rate decision odds are tight, NZD set for a wild ride

It did turn out to be an understatement. 

Analysts expect RV companies to raise equity
Property

Analysts expect RV companies to raise equity

“We expect investor support for a capital raise," Jarden's Arie Dekker said.